X4 Pharmaceuticals (XFOR) Common Equity (2017 - 2026)

X4 Pharmaceuticals (XFOR) has reported Common Equity for 10 consecutive years, with $155.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity rose 3814.73% year-over-year to $155.5 million; the trailing twelve-month figure through Jun 2026 stood at $155.5 million (up 3814.73% YoY), and the FY2025 full-year result was $186.3 million, up 741.08% from the prior year.
• Common Equity retreated to $155.5 million in Q2 2026 per XFOR's latest filing, from $168.4 million in the prior quarter.
• Across five years, Common Equity topped out at $186.3 million in Q4 2025 and bottomed at $1.0 million in Q1 2024.
• Historically, Common Equity has averaged $68.3 million across 5 years, with a median of $60.6 million in 2024.
• The sharpest annual moves came in 2024 and 2026: Common Equity slumped 98.0% in 2024, then soared 3814.73% in 2026.
• Over 5 years, Common Equity stood at $74.1 million in 2022, then sank by 30.99% to $51.1 million in 2023, then slumped by 56.65% to $22.1 million in 2024, then soared by 741.08% to $186.3 million in 2025, then decreased by 16.55% to $155.5 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $155.5 million, $168.4 million, and $186.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.